RBC Capital Maintains Outperform on Guardant Health, Raises Price Target to $200
Guardant Health
Guardant Health GH | 0.00 |
RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:
GH) with a Outperform and raises the price target from $185 to $200.